ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2006
Opioid receptors and signaling on cells from the immune system.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- A Systematic Review of Opioid Use Disorder and Related Biomarkers.Frontiers in psychiatry · 2021Pooled it
- Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.Frontiers in immunology · 2019Trial
- Substance abuse and inflammation: consequences beyond the brain.Trends in immunology · 2026Review
- Chronic and non-canonical cGAS-STING activation: implications for health, disease, cancer, and emerging therapeutic opportunities.Apoptosis : an international journal on programmed cell death · 2026Review
- Article
- Interactions Between Endogenous Opioids and the Immune System.Advances in neurobiology · 2024Review
- Electroacupuncture Attenuates Surgical Stress-Induced Reduction of T Lymphocytes through Modulation of Peripheral Opioid System.Chinese journal of integrative medicine · 2021Article
- The molecular neurobiology and neuropathology of opioid use disorder.Current research in neurobiology · 2021Article
- Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.Frontiers in immunology · 2021Article
- Expression of Opioid Receptors in Cells of the Immune System.International journal of molecular sciences · 2020Review
- Opioid Receptors in Immune and Glial Cells-Implications for Pain Control.Frontiers in immunology · 2020Review
- Immunomodulation Associated with Sustained-release Buprenorphine in Female CD1 Mice Challenged with Ovalbumin.Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Dual immuno-renal targeting of 7-benzylidenenaltrexone alleviates lupus nephritis via FcγRIIB and HO-1.Journal of molecular medicine (Berlin, Germany) · 2018Article
- Tramadol differentially regulates M1 and M2 macrophages from human umbilical cord blood.Inflammopharmacology · 2017Article
- Anti-nociceptive and anti-inflammatory actions of sulforaphane in chronic constriction injury-induced neuropathic pain mice.Inflammopharmacology · 2017Article
- Sex differences in innate immunity and its impact on opioid pharmacology.Journal of neuroscience research · 2017Review
- Is the experience of thermal pain genetics dependent?BioMed research international · 2015Review
- Morphine attenuates apically-directed cytokine secretion from intestinal epithelial cells in response to enteric pathogens.Pathogens (Basel, Switzerland) · 2014Article
- Opioid administration following spinal cord injury: implications for pain and locomotor recovery.Experimental neurology · 2013Review
- Role of the mu-opioid receptor in opioid modulation of immune function.Amino acids · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
This review discusses the criteria for determining whether a binding site or functional response is directly mediated by either the mu, delta, or kappa opioid receptors. In 1988, Sibinga and Goldstein published the first review that addressed whether cells from the immune system express opioid receptors. The criteria that they used, namely, structure-activity relationships, stereoselectivity, dose- and concentration-dependence, and saturability are still relevant criteria today for determining if an immunological response is mediated by either the mu, delta or kappa opioid receptors. Radioligand receptor binding studies and functional studies that clearly show the presence of an opioid receptor on immunocytes are presented. Selective agonists and antagonists for the mu, delta, and kappa opioid receptors are discussed, and the need for their use in experiments is emphasized. Conditions used in functional assays are very important. Receptor desensitization and downregulation occur within minutes after the application of an agonist. However, many immunological assays are applying an agonist for days before measuring an immunological effect. The results obtained may reflect changes that are results of receptor desensitization and/or downregulation instead of changes that are observed with acute activation of the receptor. The future of receptor pharmacology lies in the crosstalk and dimerization of G protein-coupled receptors. In transfected systems, opioid receptors have been shown to dimerize with chemokine and cannabinoid receptors, resulting in crosstalk between different types of receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.